Vol. 83, No. 3

Neutralization-Sensitive R5-Tropic Simian-Human Immunodeficiency Virus SHIV-2873Nip, Which Carries *env* Isolated from an Infant with a Recent HIV Clade C Infection[▽]

Nagadenahalli B. Siddappa,[1,2] Ruijiang Song,[1,2]† Victor G. Kramer,[1] Agnès-Laurence Chenine,[1,2] Vijayakumar Velu,[5] Helena Ong,[1] Robert A. Rasmussen,[1,2] Ricky D. Grisson,[1,2] Charles Wood,[3] Hong Zhang,[3] Chipeppo Kankasa,[4] Rama Rao Amara,[5,6] James G. Else,[7] Francis J. Novembre,[5,6] David C. Montefiori,[8] and Ruth M. Ruprecht[1,2]*

Dana-Farber Cancer Institute[1] and Harvard Medical School,[2] Boston, Massachusetts 02115; Nebraska Center for Virology and School of Biological Sciences, University of Nebraska, Lincoln, Nebraska 68588[3]; University Teaching Hospital, Lusaka, Zambia[4]; Division of Microbiology and Immunology,[5] Department of Microbiology and Immunology,[6] and Division of Animal Resources,[7] Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322; and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710[8]

Human immunodeficiency virus clade C (HIV-C) accounts for >56% of all HIV infections worldwide. To investigate vaccine safety and efficacy in nonhuman primates, a pathogenic, R5-tropic, neutralization-sensitive simian-human immunodeficiency virus (SHIV) carrying HIV-C *env* would be desirable. We have constructed SHIV-2873Ni, an R5-tropic SHIV carrying a primary pediatric HIV-C *env* gene isolated from a 2-month-old Zambian infant, who died within 1 year of birth. SHIV-2873Ni was constructed using SHIV-1157ipd3N4 (R. J. Song, A. L. Chenine, R. A. Rasmussen, C. R. Ruprecht, S. Mirshahidi, R. D. Grisson, W. Xu, J. B. Whitney, L. M. Goins, H. Ong, P. L. Li, E. Shai-Kobiler, T. Wang, C. M. McCann, H. Zhang, C. Wood, C. Kankasa, W. E. Secor, H. M. McClure, E. Strobert, J. G. Else, and R. M. Ruprecht. J. Virol. 80:8729–8738, 2006) as the backbone, since the latter contains additional NF-κB sites in the long terminal repeats to enhance viral replicative capacity. The parental virus, SHIV-2873Ni, was serially passaged through five rhesus monkeys (RMs); SHIV-2873Nip, the resulting passaged virus, was reisolated from the fourth recipient about 1 year postinoculation. SHIV-2873Nip was replication competent in RM peripheral blood mononuclear cells of all random donors tested and was exclusively R5 tropic, and its *env* gene clustered with HIV-C by phylogenetic analysis; its high sensitivity to neutralization led to classification as a tier 1 virus. Indian-origin RMs were inoculated by different mucosal routes, resulting in high peak viral RNA loads. Signs of virus-induced disease include depletion of gut CD4[+] T lymphocytes, loss of memory T cells in blood, and thrombocytopenia that resulted in fatal cerebral hemorrhage. SHIV-2873Nip is a highly replication-competent, mucosally transmissible, pathogenic R5-tropic virus that will be useful to study viral pathogenesis and to assess the efficacy of immunogens targeting HIV-C Env.

Currently, 33 million people are living with human immunodeficiency virus (HIV)/AIDS (www.unaids.org), and the majority of them live in sub-Saharan Africa and South and Southeast Asia, including China and India, where HIV subtype C (HIV-C) circulates in >90% of the HIV-infected population (UNAIDS) (50). This distribution makes HIV-C the most prevalent subtype in the global pandemic, accounting for >56% of all HIV infections worldwide (www.unaids.org). Globally, HIV is one of the leading causes of childhood morbidity and mortality. Children account for 20% of all HIV-related deaths, 7% of individuals living with HIV, and 16% of new infections annually (reviewed in references 26, 29, and 38). In sub-Saharan Africa, HIV-C is responsible for approximately 50% of all infections, and a significant number of infections are in infants and children. HIV transmission from infected mothers to their infants is the primary mode of infection in children and can occur in utero, intrapartum, or postnatally through breast milk. The use of antiretroviral drugs has successfully reduced the rate of HIV infection in infants in the developed world to approximately 1%; nevertheless, such regimens have only recently become available in many of the developing nations where mother-to-child transmission of HIV is most significant (reviewed in references 26 and 38).

Simian-human immunodeficiency viruses (SHIVs) are chimeric viruses that contain HIV envelope genes in the simian immunodeficiency virus (SIV) backbone. They have been used in a wide range of studies investigating lentiviral pathogenesis, antiviral immunity, virus-host interactions, mucosal transmission, and vaccine and drug efficacy (20). However, the majority of current SHIV strains utilize envelope genes derived from HIV clade B strains, which represent fewer than 10% of all global infections. Therefore, the available SHIV chimeras do not reflect the genetic diversity of the HIV epidemic, which is dominated by non-B clades, especially by HIV-C. Only a few studies have focused on developing anti-clade C Env vaccines (25, 27, 44, 49), with one efficacy study in primate models (44). To investigate lentiviral pathogenesis as well as anti-HIV-C vaccine safety and efficacy in nonhuman primate models, a

pathogenic, CCR5-restricted, clade C SHIV (SHIV-C) would be very useful.

Previously, we have generated an R5-tropic SHIV-C, SHIV-1157i (6, 51), which carries *env* from a 6-month-old Zambian infant born to an HIV-positive mother. During prospective long-term follow-up, this infant turned out to be a long-term nonprogressor who has remained asymptomatic at 8 years of age (61). The rhesus monkey (RM)-adapted strain, SHIV-1157ip, was pathogenic and has caused AIDS in several monkeys thus far, but with a relatively low rate of disease progression. AIDS developed in RMs between 127 and 300 weeks postinoculation (17a). A late virus was reisolated and engineered to contain extra NF-κB sites in the long terminal repeats (LTRs) (51); follow-up times for monkeys infected with this late form are not yet sufficient to assess development to AIDS, although signs of disease have developed. A possible explanation is that the *env* gene used to construct the original SHIV-1157i is an important determinant of the disease progression rate. The fact that the *env* gene was derived from a long-term nonprogressor may be linked to the relatively slow disease progression we observed in RMs infected with SHIV carrying the corresponding *env* gene.

We sought to test whether constructing an R5-tropic SHIV with an *env* gene derived from a rapid progressor would give rise to a more virulent R5-tropic SHIV-C. Although HIV- or SIV-infected individuals with either typical rates of disease progression or long-term nonprogression have been studied extensively, few reports were focused on the virologic and immunologic characteristics of patients with rapid disease progression (9, 22). Patients who progress to AIDS within 1 to 2 years from the time of infection have been identified among infants and adults (7, 13, 34, 35, 46), with a higher frequency in infant populations. These patients demonstrate rapid loss of $CD4^+$ T cells and lack potent cellular and humoral immune responses.

Here we report the construction of SHIV-2873Ni, a chimera that carries *env* of an R5-tropic HIV-C strain isolated from a rapid progressor, a 2-month-old Zambian baby who died of AIDS-related disease within 1 year of birth. SHIV-2873Ni was serially passaged through five RMs; SHIV-2873Nip, the passaged virus, was reisolated and characterized from the fourth recipient about 1 year postinoculation when signs of disease were manifest. The RM-adapted virus caused T-cell depletion within a few months postinoculation.

MATERIALS AND METHODS

Original virus isolates and nomenclature. HIV2873i is a biological isolate obtained from a Zambian infant at 2 months of age. The infant, born to an HIV-C-infected mother, was PCR negative at birth and rapidly progressed to AIDS-related death within 1 year. The designation "i" indicates a virus strain (or *env* gene) isolated from an infant. SHIV-2873Ni is the original, nonadapted infectious molecular clone that contains two NF-κB sites in the 3′ LTR instead of the usual single NF-κB site present in the SIVmac239 LTR. This duplicate NF-κB site is copied into the 5′ LTR during subsequent reverse transcription steps of the retroviral life cycle (8). SHIV-2873Nip, a biological isolate obtained after passage of SHIV-2873Ni through four RMs, was reisolated from a monkey systemically infected for approximately 1 year; "p" designates a passaged (or monkey-adapted) virus.

Cell lines, antibodies, and viruses. U87 or GHOST cell lines, which express CD4 only or CD4 with different chemokine receptors, as well as CEM.NKR.CCR5 cells, were provided by the NIH AIDS Research and Reference Reagents Program (ARRRP) (Germantown, MD). Neutralizing monoclonal antibodies (NMAbs) 2F5

(36), 2G12 (56), and 4E10 (54) were provided by Hermann Katinger (Polymune Scientific, Vienna, Austria). MAb b12 (1) is an immunoglobulin (IgG1) isotype and was produced by expression in recombinant CHO cells (kindly provided by Dennis Burton, Scripps Research Institute, La Jolla, CA). CEMx174-GFP cells, provided by Barbara Felber (National Cancer Institute, Frederick, MD), contain the green fluorescent protein (GFP) gene under HIV type 1 (HIV-1) LTR regulation and express CXCR4 but not CCR5. TZM-bl cells (also called JC53-bl [clone 13] cells; ARRRP) (11) are derived from a HeLa cell line (JC.53) that stably expresses CD4 and CCR5. TZM-bl cells also express luciferase and β-galactosidase under the control of the HIV-1 LTR.

Animals and animal care. RMs (*Macaca mulatta*) of Indian origin were used in this study. The animals were kept according to National Institutes of Health guidelines on the care and use of laboratory animals at the Yerkes National Primate Research Center (YNPRC) (Emory University, Atlanta, GA). These facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Animal experiments were approved by the Animal Care and Use Committees of Emory University and the Dana-Farber Cancer Institute.

Construction of SHIV-2873Ni molecular clones. Peripheral blood mononuclear cells (PBMC) from Zambian infant 2873i were collected 2 months after the infant was born to an HIV-positive mother (62) and were briefly cocultured with normal human donor PBMC. DNA from this coculture was extracted for PCR amplification. A pair of specific primers, designed to amplify the entire HIV-1 *env* gene, incorporated the HindIII or XhoI restriction enzyme sites and had the following sequences: 2873-HindIII, 5′-GGGGGAAGCTTATGAGAGTGATG GGGATACAGAGG-3′, and 2873-XhoI, 5′-CCCCCTCGAGTTATTGCAAAG CTGCTTCAAAGCCC-3′. The full-length HIV2873i *env* was digested with the restriction enzymes HindIII and XhoI and cloned into vector pcDNA6/myc-His B (Invitrogen, Carlsbad, CA). SHIV-1157ipd3N4 (51) carries *env* of a late-stage SHIV isolated from an RM that developed AIDS 137 weeks after inoculation of SHIV-1157i. The 2.2-kb KpnI-BamHI fragment of HIV2873i (spanning most of gp120, the entire gp41 extracellular domain, the transmembrane region, and a part of the cytoplasmic domain) was amplified to replace the corresponding region of SHIV-1157ipd3 *env*. The modified 3′ half was ligated with the 5′ half of SHIV-vpu$^+$ (23) proviral DNA to generate full-length SHIV-2873Ni (51).

Coreceptor usage of SHIV constructs. The U87 or GHOST cell lines expressing CD4 alone or CD4 and HIV-1 or SIV coreceptors were used to study virus tropism. U87.CD4, U87.CD4.CCR1, U87.CD4.CCR2, U87.CD4.CCR3, U87.CD4.CXCR4, U87.CD4.CCR5, GHOST.BOB, and GHOST.BONZO were infected with virus stock. Cells were washed and resuspended in 1 ml of fresh medium. On days 0, 2, 4, and 6, supernatants were collected for p27 titration. The molecular clones SHIV$_{SF162P3}$ (28) (clade B, R5) and SHIV-vpu$^+$ (23) (clade B, X4) were used as controls. These experiments were carried out with both SHIV-2873Ni and SHIV-2873Nip.

Serial passage of SHIV-2873Ni. RM RBl-9 was inoculated intravenously with 10 ml of a SHIV-2873Ni stock prepared from RM PBMC. After RBl-9 was confirmed virus positive by real-time reverse transcriptase PCR (17), 10 ml of blood from RBl-9 was transferred intravenously to RAg-9 at week 2 postinoculation of the donor. Three additional animals, RAi-8, RNt-9, and RGc-9, received serial blood transfers. Animal RWa-9, which had been previously exposed to parental SHIV-2873Ni but had remained uninfected, received blood from donor RAi-8. All animals were monitored for viral loads, antibody responses, and T-cell subsets.

PCR and sequencing analysis. Chromosomal DNA was extracted from 10^6 PBMC from animal RNt-9 using a DNAzol genomic DNA isolation kit (Molecular Research Center Inc., Cincinnati, OH). To analyze the molecular evolution of SHIV-2873Nip *env* during in vivo passage, two different primers were synthesized to amplify the entire *env* gene (approximately 2.5 kb) of SHIV-2873Nip isolated from the last animal, RNt-9, about 1 year postinoculation, after it had developed signs of disease. The *env* gene of SHIV-2873Nip was amplified using the pair of primers: forward (5′-CCCCCAAGCTTCCACCATGAGAGTGAA GGAGAAATATC-3′) and reverse (5′-CCCCCGAATTCCATCTTCCTCATC TATATCATCC-3′); the PCR was carried out under end point dilution conditions. The amplified fragment was cloned into the HindIII and EcoRI sites of pcDNA6/myc-His B vector for sequencing. Eight clones carrying an infectious *env* gene were randomly picked for DNA sequencing.

Phylogenetic analysis. The sequences of the *env* genes of SHIV-2873Ni, SHIV-2873Nip, other clade C SHIVs generated by us (SHIV-1157i, SHIV-1157ip, and SHIV-1157ipd3N4), and HIV1084i (14) were aligned with full-length reference sequences of several group M viruses obtained from the Los Alamos sequence database (http://hiv.lanl.gov/content/hiv-db/SUBTYPE_REF/align.html). Nucleotide sequences were gap stripped and aligned using CLUSTAL X (55), and neighbor-joining trees were generated with the Kimura two-parameter substitution model

using MEGA3.2 software (21). Pairwise evolutionary distances were estimated using DNADIST from the PHYLIP 3.6 package (12), and the reliability of the topologies was evaluated by bootstrap analysis with 100 replicates using DNADIST, NEIGHBOR, and CONSENSE.

Generation of a large-scale SHIV-2873Nip stock. A large-scale stock of the infectious, uncloned biological isolate was prepared by infecting concanavalin A-stimulated naive RM PBMC in the presence of human interleukin-2 (20 U/ml) and tumor necrosis factor alpha (10 ng/ml) using virus harvested from cocultured, infected PBMC from monkey RNt-9 approximately 1 year postinoculation. The RM PBMC-grown stock has a p27 concentration of 140 ng/ml and 4×10^6 50% tissue culture infectious doses ($TCID_{50}$) per ml as titrated in TZM-bl cells according to published protocols (11).

Neutralization assays. The neutralization sensitivity of SHIV-2873Nip was determined using both PBMC-based and TZM-bl reporter cell line-based neutralization assays, as described previously (11, 19, 24, 44, 51). In both cases, serial dilutions of either RM sera or MAbs were set up in triplicate in 96-well plates, and virus was added (50 to 200 $TCID_{50}$) and incubated for 1 h at 37°C. Either PBMC or TZM-bl cells were then added. For assays employing immune sera, neutralization titers were calculated based on virus production in wells containing sera pooled from four naive RMs as negative controls. In both assays, the concentration of serum giving 50% neutralization of virus production (50% inhibitory concentration [IC_{50}]) was calculated using the level of virus production in control wells containing the same dilution of pooled naive sera; for MAb titers, the IC_{50} was calculated based on control wells containing virus plus cells only.

For the PBMC-based assays, human PBMC were stimulated overnight with phytohemagglutinin (5 μg/ml), washed, and added to wells at 2×10^5/well. In assays testing sera, PBMC were washed in assay plates after 1 day of culture, and fresh interleukin-2 (10 U/ml)-containing medium was added; alternatively, in PBMC-based assays testing MAbs, the MAbs were not washed away but were diluted 1:1 with fresh medium daily, starting on day 3 of the experiment. Because the latter assay condition takes into account the long half-lives of antibodies, neutralization titers may differ slightly from titers measured by other methods (2, 32). Aliquots of supernatants were harvested every other day and assayed for p27 levels in wells containing only virus plus cells, and neutralization activity was measured on the culture day showing a linear phase of increase. For TZM-bl-based assays, cells were added in the presence of DEAE dextran (40 μg/ml) and washed once on day 1, luciferase substrate (Bright-Glo, Promega, Madison, WI) was added on day 2, and luciferase activity was measured in a luminometer.

Measurement of plasma viral RNA levels. Plasma viral RNA was isolated by use of the QiaAmp viral RNA minikit (Qiagen), and viral RNA levels were measured by quantitative reverse-transcriptase PCR for SIV *gag* sequences (17) at weeks 0, 1, 2, 4, and 8 and monthly thereafter. The assay sensitivity was 50 viral RNA copies/ml.

Oral and i.r. inoculation of SHIV-2873Nip. Indian-origin RMs received 3 ml or 1 ml of the large-scale virus stock by the oral or intrarectal (i.r.) route, respectively. Six additional animals received repeated weekly low-dose i.r. inoculations (up to a maximal number of five inoculations): 1,500 $TCID_{50}$ (two monkeys) and 5,000 $TCID_{50}$ (four monkeys). Our protocol stipulated that animals remaining aviremic or failing to reach plasma viral RNA levels of $\geq 10^4$ copies/ml at the 2-week time point after the fifth low-dose virus exposure would receive a single high-dose i.r. challenge (30,000 $TCID_{50}$). Blood was collected at 0, 1, 2, 4, 8, and 16 weeks and at 3-month intervals postinoculation to determine viral RNA loads and to measure T-cell subsets.

Isolation of cells from blood and rectal biopsies. PBMC were isolated using standard procedures; lymphocytes from rectal biopsies were obtained by digestion with collagenase followed by a separation step using Percoll gradients as described previously (58). Briefly, 10 to 20 pinch biopsies were collected in complete RPMI and washed two times with ice-cold Hanks balanced salt solution. Biopsies were digested with collagenase type IV (Worthington, Lakewood, NJ) and DNase I (Roche, Indianapolis, IN), passed through needles of decreasing size (16, 18, and 20 gauge; five or six times with each needle), and filtered through a 100-μm filter. Cells were suspended in 35% Percoll in phosphate-buffered saline, underlaid with 60% Percoll, and centrifuged at 2,500 rpm for 30 min. Cells from the interface were collected, washed, and resuspended in complete RPMI for analysis.

Phenotypic analysis of T cells from blood and rectum. For T-cell subset analyses, approximately 1×10^6 PBMC or lymphocytes from rectal biopsies were surface stained with the following MAbs (BD Pharmingen, San Jose, CA): anti-CD3 conjugated to Alexa 700 (clone SP34-2), anti-CD4 conjugated to peridinin chlorophyll protein (clone L-200), and anti-CD95 conjugated to allophycocyanin (clone DX2). The following MAbs were from eBiosciences (San Diego, CA): anti-CD28 conjugated to PeCy7 (clone CD28.2), anti-CCR5 conjugated to phycoerythrin (clone 3A9), and anti-CD45RA (clone ALB11). Following stain-

ing, cells were acquired using LSRII (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Treestar, Inc., San Carlos, CA). Lymphocytes were identified based on scatter pattern, and $CD3^+ CD8^- CD4^+$ cells were considered $CD4^+$ T cells, while $CD3^+ CD8^+ CD4^-$ cells were considered $CD8^+$ T cells. $CD3^+ CD4^+$ T cells were gated based on CD28 and CD95 expression to define memory $CD4^+$ T-cell subpopulations: naive ($CD28^+ CD95^-$), central memory ($CD28^+ CD95^+$), and effector memory ($CD28^- CD95^+$).

Statistical analysis. Statistical analysis was performed using Prism (GraphPad Software, version 4). Differences in percentages and numbers of lymphocytes in groups of uninfected versus SHIV-2873Nip-infected animals were compared using the Mann-Whitney test.

Nucleotide sequence accession number. The complete nucleotide sequence of the *env* gene of SHIV-2873Nip has been submitted to GenBank; the accession number is EU526392.

RESULTS

Construction of a SHIV-C carrying *env* from a pediatric rapid progressor. PBMC were collected from infant 2873i at 2 months of age and cocultured briefly with normal human donor PBMC. This infant, born to an HIV-C-positive Zambian mother, had been PCR negative at birth and became infected either intrapartum or through breast feeding. A rapid progressor, the infant died of tuberculosis within 1 year. Tuberculosis, an AIDS-defining illness, is a frequent diagnosis among HIV-infected children in Zambia. At 4 months of age, this child's PBMC contained a high copy number of HIV proviral DNA (>750 copies per 10^6 PBMC), indicative of a relatively high viral load. Of note, neither CD4 T-cell subset nor viral RNA load determinations were available at the clinic when the child presented with tuberculosis.

Primary full-length *env* genes were PCR amplified from cocultured PBMC DNA of infant 2873i and cloned into the expression vector pcDNA6/B. To identify an infectious envelope, the resultant constructs were cotransfected into 293T cells with HIV-1 ΔEN, a proviral clone with deletions of *env* and *nef* that encodes GFP in lieu of *nef*. Cell-free supernatants containing pseudotyped viruses were used to infect CEM.NKR.CCR5 cells, which were screened for GFP expression; several infectious HIV2873i *env* clones were identified (Fig. 1A, right panel). SHIV-2873Ni was constructed using a previously identified late-stage virus, SHIV-1157ipd3N4, as a backbone (Fig. 1B). After exchanging *env* inserts, the resulting chimera, SHIV-2873Ni, contained most of gp120, the entire extracellular domain, the transmembrane region, and part of the cytoplasmic tail of gp41 of the primary isolate HIV2873i.

Next, we assessed coreceptor usage of SHIV-2873Ni and SHIV-2873Nip; as a control, we also included SHIV-2873i, a virus that carries the standard SIVmac239 LTRs with only a single NF-κB site/LTR. These viruses did not replicate in any cell line lacking CCR5, including CEMx174-GFP, U87.CD4, U87.CD4.CCR1, U87.CD4.CCR2, U87.CD4.CCR3, U87.CD4.CXCR4, GHOST-BOB, and GHOST-BONZO cells (Fig. 2A). We observed productive infection only in U87.CD4.CCR5 cells (Fig. 2B), suggesting that SHIV-2873Ni exclusively used CCR5 as a coreceptor for entry.

Replication of SHIV-2873Ni in RM PBMC. We next sought to evaluate the growth of parental SHIV-2873Ni in PBMC from six randomly selected naive Indian RM donors. This virus replicated in PBMC from three donors (RQz, N713, and RCa-3) out of the six naive donors tested (data not shown), with peak p27 production in supernatant observed between

FIG. 1. Construction of SHIV-2873Ni. (A) Identification of an infectious *env* clone. Primary full-length *env* genes were PCR amplified from genomic DNA of normal human donor PBMC cocultured with infected PBMC of Zambian infant 2873i collected at 2 months of age and cloned into the expression vector pcDNA6/B. Infant 2873i was a rapid progressor who died of AIDS-related disease within 1 year of birth to an HIV-C-positive mother. To identify an infectious envelope, the resultant constructs were cotransfected into 293T cells with HIV-1 ΔEN, an infectious HIV provirus with deletions of *env* and *nef* and encoding GFP in lieu of *nef*. The resulting pseudovirus released into cell supernatants was used to infect CEM.NKR.CCR5 cells, which were screened for GFP expression. HIV-1 ΔEN cotransfected with ADA *env* was used as positive control. (B) Construction of SHIV-2873Nip. SHIV-1157ipd3N4 (51) was used as the backbone. The 2.2-kb KpnI (K)-BamHI (B) fragment of HIV2873i (spanning most of gp120, the entire gp41 extracellular domain, the transmembrane region [TM], and part of the cytoplasmic domain) was amplified to replace the corresponding region of the proviral backbone. The modified 3′ half was ligated with the 5′ half of SHIV-vpu⁺ proviral DNA to form full-length SHIV-2873Ni. NN, two NF-κB sites are present in the 3′ LTR; during viral replication, this duplication is copied into the 5′ LTR also.

days 17 and 21. These data implied that despite the introduction of extra NF-κB binding sites into the LTRs to increase viral replicative capacity (51), the new SHIV strain still needed to undergo adaptation for optimal replication in RM.

Adaptation of SHIV-2873Ni to RMs and generation of SHIV-2873Nip. Rapid animal-to-animal passage of whole blood at the time of peak viremia (week 2 postinoculation) was

used to adapt the new SHIV-C strain. This adaptation strategy selects viruses for improved replication fitness in the new host species without favoring neutralization escape variants, since neutralizing antibody responses typically take many weeks to mature. SHIV-2873Ni was passaged in five Indian-origin RMs (Fig. 3A). The initial cell-free SHIV-2873Ni viral stock was prepared in RM PBMC that were exposed to cell-free supernatant of 293T cells transfected with proviral DNA. The first macaque, RBl-9, was inoculated intravenously with 10 ml of SHIV-2873Ni stock; peak viremia reached 2.5×10^5 RNA copies/ml at week 2 postinoculation (Fig. 3B). Four additional animals were subjected to serial blood transfer (Fig. 3A), in which 10 ml of whole blood collected at week 2 postinoculation was directly transferred into recipients RAg-9, RAi-8, RWa-9, RNt-9, and RQc-9. Animal RWa-9 had been previously exposed to supernatant of 293T cells transfected with SHIV-2873Ni proviral DNA but had remained uninfected. After receiving infected blood from RM RAi-8, animal RWa-9 became infected, as did all monkeys enrolled in the serial virus passage described in Fig. 3A. All six animals seroconverted (data not shown). The passaged virus reached the highest peak viremia level in the last recipient, monkey RQc-9. We reisolated a virus about 1 year later from monkey RNt-9, the penultimate virus recipient in the adaptation schema. This animal was persistently viremic and had signs of disease progression at that time. The passaged virus, SHIV-2873Nip, is an uncloned biological isolate that was able to replicate in PBMC of 10 out of 10 RM donors (data not shown), indicating its adaptation to the new host species, although there was donor-to-donor variability in virus replication as expected for outbred animals.

Phylogenetic analysis. Primary full-length *env* genes were amplified from genomic DNA by PCR, cloned into the expression vector pcDNA6/B, and tested for infectivity. Infectious *env* genes of the various SHIV strains were sequenced, and phylogenetic analysis was performed using Clustal W and Paup. The *env* genes of the newly created SHIV strains clustered with HIV-C; among the strains tested, the closest relationship was found with our other set of SHIV-Cs derived from a pediatric HIV-C strain isolated from an infant of the same cohort of HIV-infected mothers/infants followed prospectively


FIG. 2. Coreceptor usage of SHIV-2873i, SHIV-2873Ni, and SHIV-2873Nip. U87.CD4.CXCR4 cells (A) and U87.CD4.CCR5 cells (B) were exposed to SHIV-2873Ni, SHIV-2873Nip, SHIV$_{SF162}$ (HIV clade B *env*, R5), and SHIV-vpu⁺ (HIV clade B *env*, X4). The levels of p27 Gag were measured in the supernatants as indicated. SHIV-2873i contains the standard SIVmac239 LTRs with only a single NF-κB site/LTR; it was built using SHIV-vpu⁺ as the backbone.

FIG. 3. Serial passage of SHIV-2873Ni in RMs. (A) SHIV-2873Ni was passaged in five Indian-origin RMs through serial blood transfer. Animal RWa-9 had been exposed previously to SHIV-2873Ni but had remained uninfected. After receiving blood from donor RAi-8, RM RWa-9 and all monkeys shown in Fig. 2A became infected. (B) Viral loads were measured after serial passage at the time points indicated. †, monkey RNt-9 developed fatal cerebral hemorrhages due to severe thrombocytopenia at week 92 postinoculation. (C and D) Absolute $CD4^+$ T-cell numbers, platelet counts, and $CD4^+CD29^+$ memory T cells were assessed during the course of the infection. The dashed line denotes the lowest normal value (10%) for the $CD4^+CD29^+$ T cells.

at the University Hospital in Lusaka, Zambia. Thus, the proximity of the SHIV-2873Nip and SHIV-1157ipd3N4 *env* genes on the phylogenetic tree reflects the closeness of HIV-C strains circulating within the same community (Fig. 4A). During *env* evolution in the SHIV-infected RMs, the genes diverged as expected for chronically infected hosts (Fig. 4B).

Evolution of SHIV-2873Nip Env during adaptation. Sequence analysis of SHIV-2873Nip gp160, cloned from genomic DNA of RNt-9 PBMC collected at about 1 year after blood transfer, demonstrated a number of mutations. Compared with the parental Env sequence, SHIV-2873Ni, the SHIV-2873Nip consensus sequence revealed 14 point mutations throughout gp160, a 5-amino-acid (aa) deletion at the end of V4, and a 3-aa deletion at the beginning of the V5 region (Fig. 4B).

SHIV-2873Nip exclusively uses CCR5 as coreceptor. We assessed the coreceptor usage of SHIV-2873Nip as described for Fig. 2B. We observed productive infection only in the CCR5-expressing cell line, suggesting that SHIV-2873Nip maintained R5 tropism after rapid animal-to-animal passage.

Susceptibility of SHIV-2873Ni and SHIV-2873Nip to neutralization by human NMAbs. If SHIV-2873Nip is to become a useful tool to assess vaccine efficacy against HIV-C, maintaining a neutralization-sensitive Env structure will be important for its use as challenge virus. First, we determined the susceptibility of SHIV-2873Ni and the passaged SHIV-2873Nip to the broadly reactive human NMAbs IgG1b12, 2G12, 2F5, and 4E10 in human PBMC; the IC_{50}s were compared to those of SHIV-1157ipd3N4 (45), an infectious molecular clade C SHIV clone created by our group earlier. These NMAbs recognize conserved epitopes on HIV gp120 and on the extracellular domain of gp41. IgG1b12 targets the CD4 receptor binding site (63), 2G12 recognizes conserved mannan residues on gp120 (48), and 2F5, and 4E10 recognize a coiled-coil region on gp41 that plays a crucial role during virus fusion with the cell membrane (41, 54, 64, 65).

SHIV-2873Ni and SHIV-2873Nip were effectively neutralized by IgG1b12, 2F5, and 4E10 but not by 2G12 (Table 1) in PBMC-based assays. The parental SHIV-2873Ni had a neu-

FIG. 4. (A) Phylogenetic tree showing the relationship between SHIV-2873Ni and SHIV-2873Nip Env sequences and those of other primary strains of HIV. Phylogenetic trees were constructed from full-length Env sequences by using the neighbor-joining method. Major subtypes of HIV group M were used as reference sequences; sequences from SHIV-1157i, SHIV-1157ip, SHIV-1157ipd3N4 (51), and HIV1084i (14) were also included, since HIV1084i and the *env* genes in these SHIVs had been derived from the same cohort of infected mothers and their infants in Lusaka, Zambia. The scale bar indicates the genetic distance along the horizontal branches, and the numbers at the nodes are bootstrap values. (B) Evolution of SHIV-2873Nip Env during passage and replication in monkey RNt-9. The deletions of 5 and 3 aa at the end and beginning of the V4 and V5 domains of gp120, respectively, in the adapted SHIV-2873Nip are shown. The Env consensus sequence for SHIV-2873Nip was derived by sequencing eight individual clones carrying infectious *env* genes.

tralization profile that was similar to that of SHIV-2873Nip. The IC_{50}s for SHIV-2873Ni and SHIV-2873Nip obtained with NMAbs IgG1b12, 2F5, and 4E10 were generally lower than those for SHIV-1157ipd3N4 (Table 1). Similar results were obtained using RM PBMC in the neutralization assays. We could not assess the neutralization sensitivity of SHIV-2873Ni in RM PBMC, since this parental, nonadapted virus did not replicate in the RM donor PBMC pool tested. Of note, none of the SHIV-Cs tested were susceptible to NMAb 2G12. Its epitope includes N-linked mannan moieties associated with the five residues N295, N332, N339, N386, and N392, with glycans attached to N295, N332, and N392 contributing to a core epitope (47, 48). Only four of these five residues are present in

SHIV-2873Ni and SHIV-2873Nip Env sequences, and the crucial N295 residue was replaced by T295. The 2G12 epitope has been found to be missing in many primary HIV-C isolates (24). Compared with the linear motif NWFDIT recognized by 4E10, two amino acids (S versus D and S versus T) of this epitope were different in the predicted SHIV-2873Ni and SHIV-2873Nip Env sequences. In addition, these residues are not among the crucial residues of this epitope (64). With regard to the linear epitope ELDKWA recognized by 2F5, ALDSWN was found in both SHIV-2873Ni and SHIV-2873Nip with three residue substitutions compared to the standard epitope (4). The DSW motif, instead of DKW, may affect 2F5 binding efficiency.

TABLE 1. Neutralization of clade C SHIV strains in human and RM PBMC

Source of Abs (human NMAb or RM name)	IC$_{50}$ (μg/ml or reciprocal dilution)[a]					
	SHIV-2873Ni		SHIV-2873Nip		SHIV-1157ipd3N4	
	Human PBMC	RM PBMC	Human PBMC	RM PBMC	Human PBMC	RM PBMC
Human NMAbs						
IgG1b12	0.36	ND	0.4	0.03	1.3	0.48
2G12	>40	ND	>40	>40	>40	>40
2F5	0.32	ND	0.3	0.18	0.67	2.0
4E10	0.035	ND	0.035	0.05	0.15	0.43
4×[b]	0.40	ND	0.09	0.05	0.15	0.19
Polyclonal RM plasma/sera						
Autologous plasma samples						
RNt-9 (time of virus isolation)	ND	ND	662	ND	ND	ND
RNt-9 (10 mo after virus isolation)	ND	ND	1,036	ND	ND	ND
Heterologous sera						
RHy-9 (SHIV-1157ipd3N4-infected RM)[c]	ND	ND	3,722	ND	>10,240	ND
RJa-9 (SHIV-1157ip-infected RM)	ND	ND	2,048	ND	>10,240	ND

[a] Values are concentrations (μg/ml) (for NMAbs IgG1b12, 2G12, and 4E10) or dilutions (for plasma or serum samples). All three viruses lack the 2G12 epitope. ND, not determined.
[b] 4×, quadruple combination of IgG1b12, 2G12, 2F5, and 4E10 at a 1:1:1:1 ratio.
[c] RHy-9 was described by Rasmussen et al. (44).

Susceptibility of SHIV-2873Nip to neutralization by autologous and heterologous RM plasma/sera. To test the susceptibility of SHIV-2873Nip to neutralization by polyclonal antibodies, we performed a series of PBMC- and TZM-bl-based neutralization assays with autologous and heterologous RM plasma or serum samples. Autologous RM plasma samples from monkey RNt-9 were tested at the time of virus isolation and 10 months later. Virus was tested in the presence of plasma from naive controls and experimental animals; the ratio of the two values was used to calculate the percent inhibition. SHIV-2873Nip could be neutralized by autologous plasma (Table 1), and the NAb titers in the RM increased with time. Sera from RM chronically infected with an earlier form of SHIV-1157ipd3N4 potently neutralized SHIV-2873Nip (Table 1 [data for only two RMs are shown]). Similar results were

obtained using the TZM-bl neutralization assay (data not shown).

Neutralization tier assignment. Recently, a tier system has been developed to differentiate the neutralization sensitivities of primary HIV or SHIV strains (30). Tier 1 strains are noticeably neutralization sensitive; tier 2 strains are more difficult to neutralize and represent average sensitivity for primary isolates. To assess the neutralization sensitivity, we have tested SHIV-2873Nip against a panel of human NMAbs and polyclonal sera collected from HIV-positive individuals in TZM-bl cells. According to the data in Table 2, SHIV-2873Nip was classified as a tier 1 virus and our "late-stage" virus, SHIV-1157ipd3N4, falls into tier 2. SHIV$_{SF162P3}$ and SHIV$_{SF162P4}$, which had been classified previously as tier 2 and tier 1 viruses, respectively, were used for comparison in the assay.

TABLE 2. Neutralization sensitivity of R5-tropic SHIV strains carrying HIV clade B or C *env* to soluble CD4, human NMAbs, and serum samples

SHIV strain	Clade	IC$_{50}$ in TZM-bl cells[a]													Tier
		μg/ml						Reciprocal serum dilution							
		Soluble CD4	IgG1b12	2G12	2F5	4E10	HIVIG	BB47	BB55	BB68	BB75	BB80	BB81	BB87	
SHIV-2873Nip (Zambian env; early isolate)	C	0.1	0.5	>25	>25	>25	16.8	340	876	509	716	1,273	157	876	1
SHIV-1157ipd3N4 (Zambian env; late isolate)	C	0.4	7.0	>25	>25	>25	1,160	105	131	86	79	72	47	260	2
SHIV$_{SF162P4}$	B	0.2	<0.01	15.7	1.5	0.7	25	363	2,543	328	615	828	211	360	1
SHIV$_{SF162P3}$	B	11.6	6.0	>25	>25	>25	1,505	24	65	22	27	25	<20	180	2

[a] Values represent the concentration (μg/ml for soluble CD4 and human NMAbs IgG1b12, 2G12, 2F5, and 4E10 and HIVIG) or the dilution (for serum samples) at which relative luciferase units were reduced 50% compared to virus control wells. BB47, BB55, BB68, BB75, BB80, BB81, and BB87 are serum samples from individuals infected with HIV-1 clade C.

FIG. 5. Oral and i.r. inoculation of SHIV-2873Nip. Two monkeys (RBg-10 and RUf-10) were inoculated orally or i.r., respectively, with SHIV-2873Nip stock. (B) Six monkeys were used in a repeated low-dose i.r. titration; the aim was to find a virus dose leading to systemic infection (defined as a viral RNA level of $\geq 10^4$ copies/ml) after a maximum of five weekly i.r. inoculations. Monkeys remaining uninfected at week 2 after the fifth weekly low-dose virus challenge were given a single high dose of SHIV-2873Nip (30,000 $TCID_{50}$). Viral loads were measured at the time points indicated. The horizontal dotted line indicates the lower limit of detection (<50 viral RNA copies/ml). (C and D) Estimation of $CD4^+$ T-cell loss in gut (C) and blood (D), showing levels of $CD4^+$ T cells in rectal biopsy specimens (collected between weeks 6 and 12 after the last, successful inoculation) and blood of RMs inoculated with SHIV-2873Nip compared with uninfected controls. The asterisk in panel C designates the percent $CD4^+$ T cells in rectal mucosa of monkey RNt-9 collected at week 84 postinoculation.

Mucosal transmissibility of SHIV-2873Nip. Since approximately 90% of all new HIV infections are acquired by mucosal exposure during sexual contact or via mother-to-child transmission, candidate AIDS vaccines should protect against mucosal virus challenge. Preclinical vaccine safety and efficacy studies in primate models should thus focus on mucosal virus challenges (reviewed in reference 59). We sought to test whether SHIV-2873Nip could be transmitted mucosally. A large stock of SHIV-2873Nip was generated in RM PBMC. To demonstrate mucosal transmissibility, we inoculated one monkey each by the oral and i.r. routes. Both animals showed robust viral replication during the first 2 weeks postinoculation (Fig. 5A). Next, we sought to determine whether SHIV-2873Nip could lead to systemic infection after repeated weekly low-dose i.r. challenges; we set five weekly inoculations as maximum. Of two RMs exposed to a weekly dose of 1,500 $TCID_{50}$, one animal became viremic after three inoculations, whereas the second one did not and was subsequently given a single dose of 30,000 $TCID_{50}$, which promptly led to high viremia. Another four RMs were challenged weekly with 5,000 $TCID_{50}$; all became viremic after one or four inoculations, respectively (Fig. 5B). These data indicate that SHIV-2873Nip can be transmitted reproducibly by mucosal challenge.

Signs of SHIV-2873Nip pathogenicity. Animal RNt-9, the penultimate recipient during serial passage, developed thrombocytopenia at 36 weeks postinoculation; the platelet count never recovered (Fig. 3C). At 92 weeks postinoculation, the monkey was found unresponsive with epistaxis, tachypnea, and an abnormal pulmonary exam by auscultation. At necropsy, severe multifocal cerebral hemorrhages were noted as well as extensive petechial or multifocal ecchymotic hemorrhages involving the myocardium, stomach, liver, cecal mucosa, both lungs, and the bladder. The stomach also showed severe ulceration. Clearly, the monkey had developed a fatal thrombocytopenia. Although the absolute number of peripheral blood $CD4^+$ T cells remained normal, the $CD4^+CD29^+$ memory T-cell subset was persistently low from 26 weeks postinoculation onwards (Fig. 3D). Although most lymph nodes were normal at necropsy, splenomegaly was observed.

To assess the effect of SHIV-2873Nip on gut lymphocytes, all six of the mucosally inoculated RMs underwent rectal biopsies between weeks 6 and 12 postinfection; animal RNt-9 was subjected to rectal biopsy at week 84 postinfection (8 weeks before the fatal cerebral hemorrhage). We observed significant depletion of gut $CD4^+$ T cells in all monkeys compared to uninfected controls ($n = 7$; $P = 0.0006$ by Mann-Whitney test) (Fig. 5C). In contrast, no statistically significant differences were noted in the blood (Fig. 5D); thus far, all of the SHIV-2873Nip-infected monkeys have maintained normal absolute $CD4^+$ T-cell counts. However, four of the SHIV-2873Nip-infected animals (RWl-11, RAb-11, RTb-11, and RMs-11) demonstrated loss of peripheral blood $CD4^+$ memory T cells as assessed by $CD4^+CD29^+$ double staining (data not shown).

DISCUSSION

Here, we describe the development of a new R5-tropic SHIV-C that carries an African pediatric HIV-C *env*. The newly constructed molecular clone, SHIV-2873Ni, and the biological isolate, SHIV-2873Nip, have a number of relevant characteristics: (i) SHIV-2873Ni carries an HIV-C *env* from a pediatric rapid progressor; (ii) SHIV-2873Ni was cloned using the SHIV-1157ipd3N4 backbone, which has a deletion in the 3' end of HIV *env* that restored the original SIV *env* C terminus extending into *nef*; (iii) SHIV-2873Ni and its passaged progeny contain extra NF-κB sites; (iv) SHIV-2873Nip retained exclusive R5 tropism; (v) SHIV-2873Nip showed signs of pathogenicity (memory T-cell depletion, loss of CD4$^+$ T cells in rectal tissues, and severe, fatal thrombocytopenia); and (vi) SHIV-2873Nip was mucosally transmissible and neutralization sensitive with a tier 1 profile.

SHIV-2873Nip carries the envelope gene of a pediatric HIV-C, the most prevalent strain worldwide. Although other SHIV strains (SHIV$_{CHN19}$, SHIV$_{MJ4}$, SHIV-MCGP1.3, and SHIV-XJ02170) encoding clade C envelopes have been created, they are either dual tropic (SHIV-MCGP1.3) (4), unable to replicate in RM PBMC (SHIV$_{CHN19}$) (5), or difficult to reisolate postadaptation (SHIV$_{MJ4}$ and SHIV-XJ02170) (37, 60). In contrast, SHIV-2873Nip was mucosally transmissible and was able to replicate vigorously in PBMC of all RM donors tested, indicating effective adaptation to the new host species. Only one other SHIV-C strain, SHIV-1157ipd3N4 (51), is exclusively R5 tropic and highly replication competent in RMs.

Genetic analysis of SHIV-2873Nip *env* showed a 5-aa deletion in the V4 region, a 3-aa deletion at the beginning of V5, and 14 point mutations throughout gp160. Interestingly, Env was still functional in the pseudotype virus assays in vitro despite these deletions. In all monkeys infected mucosally, SHIV-2873Nip replicated vigorously (peak viral RNA levels of 2.1×10^5 to 9.5×10^6 copies/ml). Since most new HIV infections worldwide are acquired mucosally, mucosal transmission should be employed to assess vaccine efficacy. Clearly, SHIV-2873Nip showed reproducible mucosal transmissibility.

SHIV-2873Nip showed clear signs of pathogenicity within a few months postinoculation. Studies with SIV-infected RMs and HIV-infected humans have documented that acute infection is accompanied by a marked depletion of CD4$^+$ memory T cells, primarily in mucosal tissues (3, 31, 57). We observed loss of memory CD4$^+$CD29$^+$ T cells in peripheral blood and depletion of CD4$^+$ T cells in the gut tissues of all SHIV-2873Nip-infected RMs. This SHIV-C targets memory CD4$^+$ T cells, whereas the acutely pathogenic, X4- or dual-tropic SHIVs that have been used frequently in vaccine efficacy studies in nonhuman primate models predominantly affect naive CD4$^+$ T cells (16, 39) and induce precipitous drops in peripheral blood CD4$^+$ T cells that are irreversible in most RMs (43, 45, 53). In contrast, SHIV-2873Nip does not induce acute, severe lymphocyte depletion, suggesting that this new R5-tropic SHIV-C exhibits biological characteristics that mimic HIV disease progression in humans. Another R5-tropic SHIV that carries an HIV clade B *env*, SHIV$_{SF162P3}$, also induces gradual CD4$^+$ T-cell loss and causes AIDS in some but not all RMs (15). Recently, Pahar et al. (40), using repeated low-dose vaginal SHIV$_{SF162P3}$ challenges, observed control of viremia in

most animals with modest depletion of the memory CD4$^+$ T-cell subsets. In our repeated low-dose i.r. challenge approach, SHIV-2873Nip led to statistically significant depletion of CD4$^+$ T cells in the gut.

SHIV-2873Nip induced fatal thrombocytopenia in one RM. Thrombocytopenia is a known complication of lentiviral infection and has been associated with all stages of HIV infection in humans (reviewed in reference 18) as well as SIV and SHIV infection in macaques (reviewed in references 17, 33, and 51). A relatively recent population-based study examined the association between AIDS and strokes; a strong link was found with both intracerebral hemorrhages and ischemic strokes (52). An earlier report described an association between thrombocytopenia and the development of intracerebral hemorrhages in patients with AIDS (42).

Our data indicate that SHIV-2873Nip is sensitive to neutralization by human NMAbs, polyclonal sera of SHIV-C-infected RM and HIV-C-infected humans, and a polyclonal high-titer anti-HIV Ig preparation (HIVIG) which had been generated from HIV clade B-infected individuals. SHIV-2873Nip was more neutralization sensitive than SHIV-1157ipd3N4. This is probably due to the fact that we reisolated SHIV-2873Nip approximately a year after RM RNt-9 became infected. In contrast, SHIV-1157ipd3N4 was generated from a virus reisolated after a significantly longer period of time from an infected RM that had progressed to AIDS at 2.7 years postinfection; SHIV-1157ipd3N4 was clearly a neutralization escape virus (51). According to an intriguing study, recently transmitted HIV-C isolates were surprisingly neutralization sensitive compared to donor virus strains (10, 24). Among discordant couples, newly infected individuals harbored more neutralization-sensitive viruses compared with the strains that predominated in their infected partners when tested against contemporaneous donor plasma, suggesting that a bottleneck effect during or shortly after sexual transmission favored neutralization-sensitive HIV-C quasispecies. The newly transmitted HIV-C strains had significantly fewer N-linked glycosylation sites and shorter variable loops than the strains that predominated in the infected source persons (10, 24).

Of note, SHIV-2873Nip was classified as a tier 1 virus based upon its susceptibility to neutralization by polyclonal sera collected from HIV-C-infected individuals, HIVIG, and NMAbs; this high neutralization sensitivity will be useful in the development of NAb response-based AIDS vaccine concepts. To date, the induction of sufficient NAb levels with extended breadth has been a major hurdle. We suggest that initial vaccine efficacy testing should make use of a tier 1 SHIV challenge virus in primate models. If protection is achieved, subsequent vaccine development steps could then use SHIV strains that are progressively more difficult to neutralize in primates. SHIV-2873Nip will be useful tool to evaluate vaccine candidates that seek to induce anti-HIV-C NAb responses, and as of today, it is the only SHIV-C tier 1 virus described.

Our in vivo data indicate that SHIV-2873Nip is a highly replication-competent R5-tropic SHIV-C. We have previously generated SHIV-1157ipd3N4, a tier 2 R5-tropic SHIV-C that is pathogenic and induces AIDS (51), although disease progression has been slow. Nevertheless, SHIV-1157ipd3N4 has been used successfully to assess the efficacy of a multigenic DNA prime/protein boost and a multigenic protein-only vac-

cine (44). The following parameters have been used as readouts of vaccine efficacy: complete protection from systemic viral infection, as well as delay and lowering of peak viremia. We posit that the same strategy can be applied to challenge studies involving the tier 1 SHIV-2873Nip. In addition, protection from depletion of gut CD4$^+$ lymphocytes could serve as a measurement of vaccine efficacy. Prolonged, prospective follow-up will reveal whether SHIV-2873Nip is more pathogenic than SHIV-1157ipd3N4.

In summary, the R5-tropic SHIV-2873Nip is a highly replication-competent, mucosally transmissible tier 1 SHIV-C that will be a useful tool to study viral pathogenesis, to assess the efficacy of immunogens targeting HIV-C Env, and to test vaccine candidates that seek to induce anti-HIV-C NAb responses.

REFERENCES

1. Barbas, C. F., III, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. Persson, P. L. Nara, E. Norrby, et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89:9339–9343.

2. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232–52.

3. Brenchley, J. M., T. W. Schacker, L. E. Ruff, D. A. Price, J. H. Taylor, G. J. Beilman, P. L. Nguyen, A. Khoruts, M. Larson, A. T. Haase, and D. C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200:749–759.

4. Cayabyab, M., D. Rohne, G. Pollakis, C. Mische, T. Messele, A. Abebe, B. Etemad-Moghadam, P. Yang, S. Henson, M. Axthelm, J. Goudsmit, N. L. Letvin, and J. Sodroski. 2004. Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian clade C HIV type 1 isolate. AIDS Res. Hum. Retroviruses 20:27–40.

5. Chen, Z., Y. Huang, X. Zhao, E. Skulsky, D. Lin, J. Ip, A. Gettie, and D. D. Ho. 2000. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). J. Virol. 74:6501–6510.

6. Chenine, A. L., K. A. Buckley, P. L. Li, R. A. Rasmussen, H. Ong, S. Jiang, T. Wang, P. Augostini, W. E. Secor, and R. M. Ruprecht. 2005. Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques. AIDS 19:1793–1797.

7. Chiappini, E., L. Galli, P. A. Tovo, C. Gabiano, G. C. Gattinara, A. Guarino, R. Badolato, C. Giaquinto, C. Lisi, and M. de Martino. 2006. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 20:207–215.

8. Coffin, J. M., S. H. Hughes, and H. E. Varmus. 1997. Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

9. Demarest, J. F., N. Jack, F. R. Cleghorn, M. L. Greenberg, T. L. Hoffman, J. S. Ottinger, L. Fantry, J. Edwards, T. R. O'Brien, K. Cao, B. Mahabir, W. A. Blattner, C. Bartholomew, and K. J. Weinhold. 2001. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res. Hum. Retroviruses 17:1333–1344.

10. Derdeyn, C. A., J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, G. M. Shaw, B. T. Korber, S. Allen, and E. Hunter. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019–2022.

11. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358–8367.

12. Felsenstein, J. 1996. Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods. Methods Enzymol. 266:418–427.

13. Garland, F. C., C. F. Garland, E. D. Gorham, S. K. Brodine, et al. 1996. Western blot banding patterns of HIV rapid progressors in the U.S. Navy Seropositive Cohort: implications for vaccine development. Ann. Epidemiol. 6:341–347.

14. Grisson, R. D., A. L. Chenine, L. Y. Yeh, J. He, C. Wood, G. J. Bhat, W. Xu, C. Kankasa, and R. M. Ruprecht. 2004. Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J. Virol. 78:14066–9.

15. Harouse, J. M., A. Gettie, T. Eshetu, R. C. Tan, R. Bohm, J. Blanchard, G. Baskin, and C. Cheng-Mayer. 2001. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75:1990–1995.

16. Harouse, J. M., A. Gettie, R. C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816–819.

17. Hofmann-Lehmann, R., R. K. Swenerton, V. Liska, C. M. Leutenegger, H. Lutz, H. M. McClure, and R. M. Ruprecht. 2000. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS 17a. Res. Hum. Retroviruses 16:1247–1257.

17a. Humbert, M., R. A. Rasmussen, R. Song, H. Ong, P. Sharma, A. L. Chenine, V. G. Kramer, N. B. Siddappa, W. Xu, J. G. Else, F. J. Novembre, E. Strobert, S. P. O'Neil, and R. M. Ruprecht. 2008. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 5:94.

18. Karpatkin, S., M. Nardi, and D. Green. 2002. Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost. 88:389–401.

19. Kitabwalla, M., F. Ferrantelli, T. Wang, A. Chalmers, H. Katinger, G. Stiegler, L. A. Cavacini, T. C. Chou, and R. M. Ruprecht. 2003. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res. Hum. Retroviruses 19:125–131.

20. Kramer, V. G., N. B. Siddappa, and R. M. Ruprecht. 2007. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr. HIV Res. 5:642–655.

21. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 5:150–163.

22. Kuwata, T., H. Dehghani, C. R. Brown, R. Plishka, A. Buckler-White, T. Igarashi, J. Mattapallil, M. Roederer, and V. M. Hirsch. 2006. Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence of differential selection of RP-specific envelope mutations in vitro and in vivo. J. Virol. 80:1463–1475.

23. Li, J. T., M. Halloran, C. I. Lord, A. Watson, J. Ranchalis, M. Fung, N. L. Letvin, and J. G. Sodroski. 1995. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 69:7061–7067.

24. Li, M., J. F. Salazar-Gonzalez, C. A. Derdeyn, L. Morris, C. Williamson, J. E. Robinson, J. M. Decker, Y. Li, M. G. Salazar, V. R. Polonis, K. Mlisana, S. A. Karim, K. Hong, K. M. Greene, M. Bilska, J. Zhou, S. Allen, E. Chomba, J. Mulenga, C. Vwalika, F. Gao, M. Zhang, B. T. Korber, E. Hunter, B. H. Hahn, and D. C. Montefiori. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776–90.

25. Lian, Y., I. Srivastava, V. R. Gomez-Roman, J. Zur Megede, Y. Sun, E. Kan, S. Hilt, S. Engelbrecht, S. Himathongkham, P. A. Luciw, G. Otten, J. B. Ulmer, J. J. Donnelly, D. Rabussay, D. Montefiori, E. J. van Rensburg, and S. W. Barnett. 2005. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79:13338–49.

26. Little, K., C. Thorne, C. Luo, M. Bunders, N. Ngongo, P. McDermott, and M. L. Newell. 2007. Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr. HIV Res. 5:139–153.

27. Lockey, T. D., K. S. Slobod, T. E. Caver, S. D'Costa, R. J. Owens, H. M. McClure, R. W. Compans, and J. L. Hurwitz. 2000. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol. Res. 21:7–21.

28. Luciw, P. A., E. Pratt-Lowe, K. E. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA 92:7490–7494.

29. **Luzuriaga, K., and J. L. Sullivan.** 2002. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev. **4:**21–26.
30. **Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J. Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori.** 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. **79:**10103–7.
31. **Mattapallil, J. J., Z. Smit-McBride, M. McChesney, and S. Dandekar.** 1998. Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1β expression and display antiviral cytotoxic activity despite severe CD4$^+$ T-cell depletion in primary simian immunodeficiency virus infection. J. Virol. **72:**6421–6429.
32. **McCann, C. M., R. J. Song, and R. M. Ruprecht.** 2005. Antibodies: can they protect against HIV infection? Curr. Drug Targets Infect. Disord. **5:**95–111.
33. **McClure, H. M., D. C. Anderson, A. A. Ansari, P. N. Fultz, S. A. Klumpp, and R. F. Schinazi.** 1990. Nonhuman primate models for evaluation of AIDS therapy. Ann. N. Y. Acad. Sci. **616:**287–298.
34. **Michael, N. L., A. E. Brown, R. F. Voigt, S. S. Frankel, J. R. Mascola, K. S. Brothers, M. Louder, D. L. Birx, and S. A. Cassol.** 1997. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection—evidence for highly susceptible human hosts. J. Infect. Dis. **175:**1352–1359.
35. **Montagnier, L., C. Brenner, S. Chamaret, D. Guetard, A. Blanchard, J. de Saint Martin, J. D. Poveda, G. Pialoux, and M. L. Gougeon.** 1997. Human immunodeficiency virus infection and AIDS in a person with negative serology. J. Infect. Dis. **175:**955–959.
36. **Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger.** 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. **67:**6642–6647.
37. **Ndung'u, T., Y. Lu, B. Renjifo, N. Touzjian, N. Kushner, V. Pena-Cruz, V. A. Novitsky, T. H. Lee, and M. Essex.** 2001. Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. J. Virol. **75:**11417–25.
38. **Newell, M. L.** 2006. Current issues in the prevention of mother-to-child transmission of HIV-1 infection. Trans. R. Soc. Trop. Med. Hyg. **100:**1–5.
39. **Nishimura, Y., C. R. Brown, J. J. Mattapallil, T. Igarashi, A. Buckler-White, B. A. Lafont, V. M. Hirsch, M. Roederer, and M. A. Martin.** 2005. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc. Natl. Acad. Sci. USA **102:**8000–8005.
40. **Pahar, B., X. Wang, J. Dufour, A. A. Lackner, and R. S. Veazey.** 2007. Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology **363:**36–47.
41. **Parker, C. E., L. J. Deterding, C. Hager-Braun, J. M. Binley, N. Schulke, H. Katinger, J. P. Moore, and K. B. Tomer.** 2001. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. **75:**10906–11.
42. **Pinto, A. N.** 1996. AIDS and cerebrovascular disease. Stroke **27:**538–543.
43. **Raghavan, R., E. B. Stephens, S. V. Joag, I. Adany, D. M. Pinson, Z. Li, F. Jia, M. Sahni, C. Wang, K. Leung, L. Foresman, and O. Narayan.** 1997. Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques. Brain Pathol. **7:**851–861.
44. **Rasmussen, R. A., H. Ong, R. Song, A. L. Chenine, M. Ayash-Rashkovsky, S. L. Hu, P. Polacino, J. G. Else, F. J. Novembre, and R. M. Ruprecht.** 2007. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS **21:**1841–1848.
45. **Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin.** 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. **70:**6922–6928.
46. **Rouet, F., C. Sakarovitch, P. Msellati, N. Elenga, C. Montcho, I. Viho, S. Blanche, C. Rouzioux, F. Dabis, and V. Leroy.** 2003. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics **112:**e289.
47. **Sanders, R. W., M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O. Lloyd, P. D. Kwong, and J. P. Moore.** 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. **76:**7293–305.
48. **Scanlan, C. N., R. Pantophlet, M. R. Wormald, E. Ollmann Saphire, R. Stanfield, I. A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton.** 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. **76:**7306–7321.
49. **Seaman, M. S., L. Xu, K. Beaudry, K. L. Martin, M. H. Beddall, A. Miura, A. Sambor, B. K. Chakrabarti, Y. Huang, R. Bailer, R. A. Koup, J. R.** Mascola, G. J. Nabel, and N. L. Letvin. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. **79:**2956–2963.
50. **Siddappa, N. B., P. K. Dash, A. Mahadevan, N. Jayasuryan, F. Hu, B. Dice, R. Keefe, K. S. Satish, B. Satish, K. Sreekanthan, R. Chatterjee, K. Venu, P. Satishchandra, V. Ravi, S. K. Shankar, R. Shankarappa, and U. Ranga.** 2004. Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J. Clin. Microbiol. **42:**2742–2751.
51. **Song, R. J., A. L. Chenine, R. A. Rasmussen, C. R. Ruprecht, S. Mirshahidi, R. D. Grisson, W. Xu, J. B. Whitney, L. M. Goins, H. Ong, P. L. Li, E. Shai-Kobiler, T. Wang, C. M. McCann, H. Zhang, C. Wood, C. Kankasa, W. E. Secor, H. M. McClure, E. Strobert, J. G. Else, and R. M. Ruprecht.** 2006. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J. Virol. **80:**8729–8738.
52. **Stambas, J., S. A. Brown, A. Gutierrez, R. Sealy, W. Yue, B. Jones, T. D. Lockey, A. Zirkel, P. Freiden, B. Brown, S. Surman, C. Coleclough, K. S. Slobod, P. C. Doherty, and J. L. Hurwitz.** 2005. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine **23:**2454–2464.
53. **Stephens, E. B., S. Mukherjee, M. Sahni, W. Zhuge, R. Raghavan, D. K. Singh, K. Leung, B. Atkinson, Z. Li, S. V. Joag, Z. Q. Liu, and O. Narayan.** 1997. A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has offered cytotropism. Virology **231:**313–321.
54. **Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger.** 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses **17:**1757–1765.
55. **Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins.** 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. **25:**4876–4882.
56. **Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger.** 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. **70:**1100–1108.
57. **Veazey, R. S., M. DeMaria, L. V. Chalifoux, D. E. Shvetz, D. R. Pauley, H. L. Knight, M. Rosenzweig, R. P. Johnson, R. C. Desrosiers, and A. A. Lackner.** 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science **280:**427–431.
58. **Velu, V., S. Kannanganat, C. Ibegbu, L. Chennareddi, F. Villinger, G. J. Freeman, R. Ahmed, and R. R. Amara.** 2007. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J. Virol. **81:**5819–5828.
59. **Vlasak, J., and R. M. Ruprecht.** 2006. AIDS vaccine development and challenge viruses: getting real. AIDS **20:**2135–2140.
60. **Wu, Y., K. Hong, A. L. Chenine, J. B. Whitney, W. Xu, Q. Chen, Y. Geng, R. M. Ruprecht, and Y. Shao.** 2005. Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate. J. Med. Primatol. **34:**101–107.
61. **Zhang, H., F. Hoffmann, J. He, X. He, C. Kankasa, R. Ruprecht, J. T. West, G. Orti, and C. Wood.** 2005. Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology **2:**67.
62. **Zhang, H., F. Hoffmann, J. He, X. He, C. Kankasa, J. T. West, C. D. Mitchell, R. M. Ruprecht, G. Orti, and C. Wood.** 2006. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology **3:**73.
63. **Zhou, T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, D. R. Burton, D. S. Dimitrov, J. Sodroski, R. Wyatt, G. J. Nabel, and P. D. Kwong.** 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature **445:**732–737.
64. **Zwick, M. B., R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton.** 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. **79:**1252–1261.
65. **Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren.** 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. **75:**10892–905.

AUTHOR'S CORRECTION

Neutralization-Sensitive R5-Tropic Simian-Human Immunodeficiency Virus SHIV-2873Nip, Which Carries *env* Isolated from an Infant with a Recent HIV Clade C Infection

Nagadenahalli B. Siddappa, Ruijiang Song, Victor G. Kramer, Agnès-Laurence Chenine, Vijayakumar Velu, Helena Ong, Robert A. Rasmussen, Ricky D. Grisson, Charles Wood, Hong Zhang, Chipeppo Kankasa, Rama Rao Amara, James G. Else, Francis J. Novembre, David C. Montefiori, and Ruth M. Ruprecht

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; Nebraska Center for Virology and School of Biological Sciences, University of Nebraska, Lincoln, Nebraska 68588; University Teaching Hospital, Lusaka, Zambia; Division of Microbiology and Immunology, Department of Microbiology and Immunology, Division of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322; and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710

Volume 83, no. 3, p. 1422–1432, 2009. SHIV-2873Nip was erroneously classified as a tier 1 virus. The correct neutralization sensitivity of this virus is tier 2, as demonstrated by replicate experiments. Throughout the article, SHIV-2873Nip should be referred to as a virus with tier 2 neutralization sensitivity.

Page 1422, Abstract, line 13: "high sensitivity" should read "moderate sensitivity."

Page 1422, Abstract, line 14: "tier 1" should read "tier 2."

Page 1428, column 2, line 4 from the bottom: "tier 1" should read "tier 2."

Page 1428: Table 2 should appear as shown below.

TABLE 2. Neutralization sensitivity of R5 SHIV strains carrying HIV clade B or C *env* to soluble CD4, human NMAbs, and serum samples

SHIV strain	Clade	IC$_{50}$ in TZM-bl cells[a]													Tier
		µg/ml						Reciprocal serum dilution							
		Soluble CD4	IgGlb12	2G12	2F5	4E10	HIVIG	BB47	BB55	BB68	BB75	BB80	BB81	BB87	
SHIV-2873Nip (Zambian *env*; early isolate)	C	1.5	>25	>25	>25	>25	>2,500	<20	70	266	66	56	<20	25	2
SHIV-1157ipd3N4 (Zambian *env*; late isolate)	C	0.4	7.0	>25	>25	>25	1,160	105	131	86	79	72	47	260	2
SHIV$_{SF162P4}$	B	0.2	<0.01	15.7	1.5	0.7	25	363	2,543	328	615	828	211	3,603	1
SHIV$_{SF162P3}$	B	11.6	6.0	>25	>25	>25	1,505	24	65	22	27	25	<20	180	2

[a] Values represent the concentration (µg/ml for soluble CD4 and human NMAbs IgG1b12, 2G12, 2F5, and 4E10, and HIVIG) or the dilution (for serum samples) at which relative luciferase units were reduced 50% compared to virus control wells. BB47, BB55, BB68, BB75, BB80, BB81, and BB87 are serum samples from individuals infected with HIV-1 clade C. The data shown are representative of the results of one of two replicate experiments.

Page 1430, column 1, paragraph 1, last line: "tier 1" should read "tier 2."

Page 1430, column 2, paragraph 3, line 1: "tier 1" should read "tier 2."

Page 1430, column 2, paragraph 3, last line: "tier 1" should read "tier 2."

Page 1431, column 1, paragraph 1, line 5: "tier 1" should read "tier 2."

Page 1431, column 1, paragraph 2, line 2: "tier 1" should read "tier 2."